🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

Stereotaxis, Inc. STXS R2K

Healthcare · Medical Instruments & Supplies · United States
https://www.stereotaxis.com

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. The company offers robotic magnetic navigation (RMN) systems, such as Genesis RMN, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites; and GenesisX RMN System, which is designed to enhance the accessibility of Robotic Magnetic Navigation by reducing the lengthy construction cycle necessary to install prior generation RMN systems. It also offers Odyssey, a Synchrony and SynX Solution offer integrated, real-time information solution to manage, control, record and share procedures across networks; and x-ray systems. In addition, the company offers disposables and other accessories, including MAGiC catheter, a robotically navigated magnetic ablation catheter designed to perform minimally invasive cardiac ablation procedures; MAGiC Sweep, a mapping catheter; QuikCAS, an automated catheter advancement single-use disposable device; iCONNECT; and V-CAS devices. Further, it provides interventional devices under the Map-iT, MAGiC, and EMAGIN brands, and other related devices. It markets its products through direct sales force, distributors, and sales agents. Stereotaxis, Inc. was incorporated in 1990 and is based in Saint Louis, Missouri.

READ MORE ›
$1.98
-7.04% 1Y

Market & Price

Market Cap
$193.52M
Current Price
$1.98
High / Low (52W)
$3.57 / $1.73
Beta
1.33

Valuation

Stock P/E
-
Industry PE
23.65
Forward P/E
-
PEG Ratio
1.31
Book Value
$0.14
Price to Book
14.04
P/S
6.20
EV/EBITDA
-10.43
Dividend Yield
-

Profitability & Returns

ROCE
-73.98%
ROE
-
ROA
-24.74%
Profit Margin
-69.50%
Op Margin
-83.06%
EPS (Latest Qtr)
$-0.06
EPS (TTM)
$-0.24

Balance Sheet & Liquidity

Debt/Equity
0.27
Quick Ratio
1.05
Current Ratio
1.56
Debt
$5.28M
Total Assets
$52.25M
Current Assets
$33.85M
Working Capital
$11.49M

Ownership

Promoter Holding
15.37%
Chg in Prom Hold
-
FII / Inst Holding
44.82%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
$189.42M
Total Revenue (TTM)
$31.20M
EBITDA
$-18.16M
Free Cash Flow
$-8.82M
Operating Cash Flow
$-15.35M
Shares Outstanding
97.74M
Gross Margin
53.86%
Payout Ratio
0.00%

Growth (CAGR)

Revenue 5Y
4.78%
Profit 5Y
-6.11%
Revenue (YoY)
-15.80%
Earnings (YoY)
-

PROS

No notable strengths flagged.

CONS

  • Earnings shrank at -6.1% CAGR over 5 years.
  • Trading 44.5% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 STXS Stereotaxis, Inc. R2K 1.98 - $193.52M - -73.98% - 4.78% -6.11%
2 LLY Eli Lilly and Company SPX 1,105.00 39.21 $985.37B 0.63% 38.44% 107.46% 31.69% 48.96%
3 JNJ Johnson & Johnson SPX 225.33 26.11 $542.42B 2.38% 23.13% 26.42% 5.60% 14.32%
4 UNH UnitedHealth Group Incorporated SPX 380.31 28.66 $345.38B 2.32% 9.60% 12.18% 11.35% -15.69%
5 MRK Merck & Co., Inc. SPX 118.72 33.44 $293.22B 2.86% 20.66% 18.94% 3.12% 7.93%
6 TMO Thermo Fisher Scientific Inc. SPX 492.51 27.11 $183.03B 0.38% 9.17% 13.52% -0.27% -1.19%
7 AMGN Amgen Inc. NDXSPX 336.79 23.42 $181.77B 2.99% 18.02% 101.32% 11.77% 5.58%
8 GILD Gilead Sciences, Inc. NDXSPX 134.43 18.29 $166.90B 2.44% 22.92% 43.36% 2.57% 22.83%
9 ISRG Intuitive Surgical, Inc. NDXSPXAI 424.64 51.53 $150.39B - 15.96% 17.23% 17.39% 29.26%
Ad space

Quarterly Results

Figures in USD.

Metric Dec 2013Mar 2014Jun 2014Sep 2014Dec 2014Mar 2015Jun 2015Sep 2015Mar 2016Jun 2016Sep 2016Mar 2017Jun 2017Sep 2017Mar 2018Jun 2018Sep 2018Mar 2019Jun 2019Sep 2019Mar 2020Jun 2020Sep 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue -----------6.98M--6.97M7.55M7.56M7.01M6.80M8.20M5.76M5.35M8.70M8.62M9.05M9.11M7.04M6.15M7.66M6.55M7.86M7.80M6.88M4.50M-7.47M8.80M7.46M8.64M6.29M
Cost of Revenue -----------------------------------3.41M4.22M3.36M4.32M2.50M
Gross Profit 6.23M6.74M6.06M6.52M7.47M6.90M6.72M6.83M6.47M6.78M6.08M5.72M6.26M6.22M5.71M6.16M5.92M5.60M5.65M6.37M4.80M4.26M4.68M6.02M6.53M4.73M4.92M4.67M4.57M3.88M4.19M4.06M3.97M3.31M-4.06M4.58M4.10M4.33M3.79M
Operating Expenses -----------------------------------9.99M8.56M10.66M9.98M9.78M
Operating Income --2.23M-2.29M-1.18M--1.41M-1.72M-907.48K-1.49M-1.64M-1.17M-1.90M-434.78K167.80K-1.13M-626.06K-113.78K-2.14M-1.46M-41.21K-2.05M-1.92M-1.56M-1.53M-3.39M-4.62M-4.09M-5.18M-5.05M-5.62M-5.28M-5.64M-4.75M-6.02M--5.93M-3.98M-6.56M-5.65M-5.98M
EBITDA ------------------------------------5.56M-3.58M-6.17M-5.25M-5.59M
Interest Expense ----------------------------------------
Pretax Income ------------------------------------5.82M-3.83M-6.46M-5.53M-5.86M
Tax Provision ----------------------------------------
Net Income -3.96M-4.14M-1.94M22.67K856.22K-3.14M-1.54M-996.93K-2.27M-2.33M-6.21M1.18M-177.30K-4.33M1.44M-632.21K-116.30K-2.12M-1.43M43.75K-1.97M-1.92M-1.57M-1.53M-1.21M-4.62M-4.09M-5.13M-4.92M-5.35M-4.96M-5.37M-4.51M-5.83M--5.82M-3.83M-6.46M-5.53M-5.86M
Diluted EPS -0.23-0.21-0.100.000.04-0.15-0.07-0.05-0.11-0.11-0.560.01-0.02-0.210.01-0.02-0.01-0.04-0.030.00-0.03-0.03-0.03-0.02-0.02-0.07-0.06-0.07-0.07-0.07-0.07-0.07-0.06-0.07--0.07-0.05-0.07-0.06-0.06
R&D Expense -1.50M1.31M1.21M-1.49M1.42M1.49M1.47M1.42M1.30M1.60M1.76M1.62M1.96M2.03M2.00M2.96M2.70M1.75M2.11M1.98M1.95M2.37M2.72M2.50M2.45M2.89M2.82M2.75M2.65M2.67M2.24M2.27M2.45M2.35M1.78M2.55M-2.40M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue ---------29.35M28.90M26.63M-28.15M26.77M26.92M32.38M
Cost of Revenue -------------9.68M11.91M12.32M15.31M
Gross Profit 34.13M38.49M29.49M31.78M27.03M26.79M27.24M24.63M20.39M23.63M22.77M18.97M-18.47M14.86M14.59M17.07M
Operating Expenses -------------37.25M36.70M39.33M39.18M
Operating Income -23.84M-18.96M-31.94M-10.63M-8.84M-5.38M-5.41M-6.43M-5.92M-2.46M-4.83M-6.71M--18.78M-21.84M-24.74M-22.11M
EBITDA --------------18.35M-21.24M-23.77M-20.56M
Interest Expense -----------------
Pretax Income --------------18.29M-20.71M-24.05M-21.64M
Tax Provision -----------------
Net Income -27.49M-19.92M-32.03M-9.24M-68.76M-5.20M-7.35M-5.29M-5.89M116.76K-4.59M-6.65M--18.29M-20.71M-24.05M-21.64M
Diluted EPS --3.94-5.84-1.33-5.95-0.26-0.35-0.54-0.32-0.03-0.10-0.11--0.26-0.27-0.30-0.25
R&D Expense 14.26M12.24M12.89M8.41M5.67M5.16M6.25M5.49M6.70M8.22M9.02M8.14M10.20M10.56M10.27M9.76M9.38M

Compounded Sales Growth

5 Years:4.78%
1 Year:-15.80%

Compounded Profit Growth

5 Years:-6.11%
1 Year:-

Stock Price Performance

1 Year:-7.04%
6 Months:-19.84%
3 Months:-8.33%
1 Month:+8.79%

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --65.76M39.93M32.17M31.08M23.88M18.88M20.97M10.67M18.51M43.58M55.46M-53.41M41.91M46.72M52.25M
Current Assets --------------43.25M33.27M26.44M33.85M
Cash & Equivalents 30.36M30.55M35.25M13.95M7.78M13.78M7.27M5.59M8.50M3.69M10.80M30.18M43.94M-8.59M19.82M12.22M13.42M
Inventory --------------7.88M8.43M8.33M9.57M
Receivables --------------5.09M3.82M3.82M5.85M
Total Liabilities ------36.43M36.50M36.50M31.27M11.24M15.06M15.23M-21.48M19.99M35.29M33.53M
Current Liabilities --46.80M40.83M33.65M23.80M16.41M16.14M35.65M30.13M10.19M12.16M13.57M-14.29M13.25M21.60M22.36M
Long Term Debt --8.00M17.29M16.82M18.48M18.39M18.08M----973.25K-----
Total Debt --------------5.86M5.49M6.01M5.44M
Total Equity 4.77M7.64M10.48M-18.83M-18.79M-11.70M-12.55M-17.63M-21.49M-26.57M1.31M22.77M34.62M-31.93M21.92M11.43M18.72M
Shares Outstanding --------------74.87M80.95M85.33M95.34M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow -22.31M-18.91M-31.57M-12.12M----4.67M-2.55M-4.62M-3.51M--8.41M-9.14M-8.50M-13.69M
Investing Cash Flow -1.48M-715.77K-1.03M-130.70K----81.58K-265.48K-29.49K-70.90K--22.09M19.77M74.00K-93.00K
Financing Cash Flow 23.98M24.33M11.31M6.07M----58.95K9.92M24.03M17.34M-220.00K81.00K297.00K14.76M
Capital Expenditure -------------2.38M-366.00K-34.00K-93.00K
Free Cash Flow -------------10.79M-9.51M-8.53M-13.78M
Net Change in Cash -------------30.29M10.71M-8.13M985.00K
Dividends Paid ----000---------

Ratios (Annual)

Figures in %.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % ---------80.5%78.8%71.2%-65.6%55.5%54.2%52.7%
Operating Margin % ----------8.4%-16.7%-25.2%--66.7%-81.6%-91.9%-68.3%
Net Margin % ---------0.4%-15.9%-25.0%--65.0%-77.4%-89.3%-66.8%
ROE % -359.8%-190.2%170.1%49.2%587.6%41.5%41.7%24.6%22.2%8.9%-20.2%-19.2%--57.3%-94.5%-210.3%-115.6%
ROCE % --100.0%3,546.8%714.0%-121.4%-72.0%-197.5%43.8%30.4%-29.5%-15.4%-16.0%--48.0%-76.2%-98.5%-74.0%

Shareholding Pattern

Insiders
15.37%
Institutions
44.82%
Public Float
52.96%

Top Institutional Holders

#Holder% HeldSharesValue
1 DAFNA Capital Management, LLC 20.73% 13.68M $27.09M
2 Lagoda Investment Management, L.P. 6.59% 4.35M $8.61M
3 Blackrock Inc. 5.99% 3.96M $7.83M
4 Vanguard Capital Management LLC 4.54% 3.00M $5.94M
5 Arbiter Partners Capital Management LLC 4.37% 2.88M $5.71M
6 Geode Capital Management, LLC 2.54% 1.68M $3.32M
7 Essex Investment Management Co LLC 2.41% 1.59M $3.15M
8 Archon Capital Management LLC 1.86% 1.23M $2.43M
9 Warberg Asset Management LLC 1.66% 1.09M $2.17M
10 State Street Corporation 1.45% 957.77K $1.90M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for STXS

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks